23 hours Takeda Updates On Phase 1/2 Trials Of Novavax And Moderna’s COVID-19 Vaccine Candidates In Japan Business Insider
(RTTNews) – Takeda Pharmaceutical Company Limited (TAK) said Wednesday that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan.
Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19…